Literature DB >> 35066588

RadSigBench: a framework for benchmarking functional genomics signatures of cancer cell radiosensitivity.

John D O'Connor1, Ian M Overton1, Stephen J McMahon1.   

Abstract

Multiple transcriptomic predictors of tumour cell radiosensitivity (RS) have been proposed, but they have not been benchmarked against one another or to control models. To address this, we present RadSigBench, a comprehensive benchmarking framework for RS signatures. The approach compares candidate models to those developed from randomly resampled control signatures and from cellular processes integral to the radiation response. Robust evaluation of signature accuracy, both overall and for individual tissues, is performed. The NCI60 and Cancer Cell Line Encyclopaedia datasets are integrated into our workflow. Prediction of two measures of RS is assessed: survival fraction after 2 Gy and mean inactivation dose. We apply the RadSigBench framework to seven prominent published signatures of radiation sensitivity and test for equivalence to control signatures. The mean out-of-sample R2 for the published models on test data was very poor at 0.01 (range: -0.05 to 0.09) for Cancer Cell Line Encyclopedia and 0.00 (range: -0.19 to 0.19) in the NCI60 data. The accuracy of both published and cellular process signatures investigated was equivalent to the resampled controls, suggesting that these signatures contain limited radiation-specific information. Enhanced modelling strategies are needed for effective prediction of intrinsic RS to inform clinical treatment regimes. We make recommendations for methodological improvements, for example the inclusion of perturbation data, multiomics, advanced machine learning and mechanistic modelling. Our validation framework provides for robust performance assessment of ongoing developments in intrinsic RS prediction.
© The Author(s) 2022. Published by Oxford University Press.

Entities:  

Keywords:  cancer; prediction modelling; radiation therapy; radiosensitivity; transcriptomics

Mesh:

Year:  2022        PMID: 35066588      PMCID: PMC8921666          DOI: 10.1093/bib/bbab561

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  52 in total

1.  Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

Authors:  Tobin Strom; Javier F Torres-Roca; Akash Parekh; Arash O Naghavi; Jimmy J Caudell; Daniel E Oliver; Jane L Messina; Nikhil I Khushalani; Jonathan S Zager; Amod Sarnaik; James J Mulé; Andy M Trotti; Steven A Eschrich; Vernon K Sondak; Louis B Harrison
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

Review 2.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

3.  A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.

Authors:  Bum-Sup Jang; In Ah Kim
Journal:  Radiother Oncol       Date:  2017-06-01       Impact factor: 6.280

4.  Validation of a radiosensitivity molecular signature in breast cancer.

Authors:  Steven A Eschrich; William J Fulp; Yudi Pawitan; John A Foekens; Marcel Smid; John W M Martens; Michelle Echevarria; Vidya Kamath; Ji-Hyun Lee; Eleanor E Harris; Jonas Bergh; Javier F Torres-Roca
Journal:  Clin Cancer Res       Date:  2012-07-25       Impact factor: 12.531

5.  Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen.

Authors:  Sally A Amundson; Khanh T Do; Lisa C Vinikoor; R Anthony Lee; Christine A Koch-Paiz; Jaeyong Ahn; Mark Reimers; Yidong Chen; Dominic A Scudiero; John N Weinstein; Jeffrey M Trent; Michael L Bittner; Paul S Meltzer; Albert J Fornace
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

6.  Deep learning for drug response prediction in cancer.

Authors:  Delora Baptista; Pedro G Ferreira; Miguel Rocha
Journal:  Brief Bioinform       Date:  2021-01-18       Impact factor: 11.622

7.  Most random gene expression signatures are significantly associated with breast cancer outcome.

Authors:  David Venet; Jacques E Dumont; Vincent Detours
Journal:  PLoS Comput Biol       Date:  2011-10-20       Impact factor: 4.475

8.  A genetic basis for the variation in the vulnerability of cancer to DNA damage.

Authors:  Brian D Yard; Drew J Adams; Eui Kyu Chie; Pablo Tamayo; Jessica S Battaglia; Priyanka Gopal; Kevin Rogacki; Bradley E Pearson; James Phillips; Daniel P Raymond; Nathan A Pennell; Francisco Almeida; Jaime H Cheah; Paul A Clemons; Alykhan Shamji; Craig D Peacock; Stuart L Schreiber; Peter S Hammerman; Mohamed E Abazeed
Journal:  Nat Commun       Date:  2016-04-25       Impact factor: 14.919

Review 9.  How rapid advances in imaging are defining the future of precision radiation oncology.

Authors:  Laura Beaton; Steve Bandula; Mark N Gaze; Ricky A Sharma
Journal:  Br J Cancer       Date:  2019-03-26       Impact factor: 7.640

10.  DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.

Authors:  Emil Mladenov; Simon Magin; Aashish Soni; George Iliakis
Journal:  Front Oncol       Date:  2013-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.